1. Based on current figures, an American patient in which of the following populations would be most likely to have an HIV infection?
A. African American child
B. African American man who has sex with men
C. White woman who abuses injectable drugs
D. Homeless patient
2. Patients who are newly infected with HIV will often have a “negative result” when using a rapid test. What phenomenon best explains this?
A. The specificity of the test is poor
B. The test is conducted during the window period
C. The sensitivity of the test is poor
D. The results are compromised by the Jarisch-Herxheimer reaction
3. Which drug therapy is approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis?
A. Tenofovir disoproxil fumarate/emtricitabine
B. Tenofovir alafenamide/emtricitabine
C. Tenofovir disoproxil fumarate/lamivudine
D. Tenofovir alafenamide/emtricitabine/bictegravir
4. Which class is recommended for inclusion as part of a first-line regimen for treatment of HIV?
A. Nonnucleoside reverse transcriptase inhibitors
B. Protease inhibitors
C. Integrase inhibitors
D. C-C chemokine receptor type 5 antagonists
5. When should patients should be screened for antiretroviral resistance?
A. Before initiating antiretroviral therapy
B. If adverse effects occur
C. Before initiating preexposure prophylaxis
D. If therapy failures occur
6. Which of the following regimens should be taken with a meal?
A. Tenofovir alafenamide/emtricitabine plus raltegravir
B. Tenofovir alafenamide/emtricitabine/rilpivirine
C. Tenofovir disoproxil fumarate/emtricitabine/doravirine
D. Tenofovir disoproxil fumarate/emtricitabine/efavirenz
7. Which opportunistic infection requires prophylaxis when the CD4 count falls below 200 cells/mm3 ?
A. Cryptococcal meningitis
B. Tuberculosis
C. Mycobacterium avium complex
D. Pneumocystis jirovecii
8. Which regimen would be most likely to result in significant drug-drug interactions?
A. Tenofovir alafenamide/emtricitabine/bictegravir
B. Tenofovir alafenamide/emtricitabine/rilpivirine
C. Tenofovir alafenamide/emtricitabine plus dolutegravir
D. Tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat
9. Which regimen would be preferred for a patient who experiences a needlestick from a source with unknown HIV status?
A. Tenofovir disoproxil fumarate/emtricitabine/bictegravir
B. Tenofovir alafenamide/emtricitabine/rilpivirine
C. Tenofovir disoproxil fumarate /emtricitabine plus raltegravir
D. Tenofovir disoproxil fumarate/emtricitabine/efavirenz
10. Which drug should be considered only for patients failing their current regimen?
A. Ibalizumab
B. Maraviroc
C. Fosamprenavir
D. Ritonavir
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
